By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nimbus Therapeutics 

25 First Street
Suite 404
Cambridge  Massachusetts  02141  U.S.A.
Phone: 857-999-2009 Fax: 617-231-0652



Company News
MA Life Science Growing: Backed By Eli Lilly (LLY) and Pfizer (PFE), Nimbus Therapeutics Bankrolls $43 Million 3/18/2015 6:10:56 AM
Nimbus Discovery Achieves First Milestone In Research Collaboration With Monsanto Company (MON) 12/10/2014 7:29:55 AM
Nimbus Discovery Appoints Donald Nicholson, Ph.D. As Chief Executive Officer 9/30/2014 6:27:08 AM
Nimbus Discovery To Present Data Showing That Selective ACC Inhibitors Dramatically Impact Tumor Growth In Pre-Clinical Models At American Association for Cancer Research Annual Meeting 2014 4/2/2014 9:37:38 AM
Nimbus Discovery IRAK4 Inhibitor Demonstrates Synergistic Effects In Preclinical Studies With Three Kinase Inhibitors For The Treatment Of Lymphoid Malignancies 12/9/2013 9:52:55 AM
Nimbus Discovery Advances Broad Portfolio of ACC Inhibitors for Potential Treatment of Diabetes, NASH and Liver Cancer 11/1/2013 9:55:29 AM
Nimbus Discovery and Monsanto Company (MON) Announce Collaboration 6/27/2013 9:58:56 AM
Nimbus Discovery Presents Compelling Preclinical Proof of Concept Data on Novel ACC Allosteric Inhibitor ND-630 6/24/2013 11:23:29 AM
Nimbus Discovery Announces Agreement With Shire plc to Co-Develop Therapies for Rare Diseases 5/8/2013 10:58:44 AM
Nimbus Discovery Appoints William F. Westlin, Ph.D., as Head of Preclinical Research and Early Development 2/6/2013 9:31:28 AM